Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APX005M + Pembrolizumab in Metastatic Melanoma
NCT02706353Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2017
- Primary completion
- Mar 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sotigalimab in melanoma, sponsored by University of Texas MD Anderson Cancer Center. Started Jun 2017; status: terminated.
02
Drugs
sotigalimab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02706353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02706353.